糞便カルプロテクチン検査市場規模、シェア、動向分析レポート：アッセイ別、最終用途別、地域別、セグメント別予測、2025年～2030年

糞便カルプロテクチン検査市場の成長と動向

Grand View Research, Inc.の最新レポートによると、糞便カルプロテクチン検査の世界市場規模は、2025～2030年にかけて11.2%のCAGRを記録し、2030年までに95億5,000万米ドルに達する見込みです。

世界で最も一般的ながんの1つとなっている大腸がんの罹患率の増加が、市場成長の主要要因です。医療システムが患者の転帰を改善し医療費を削減するために早期発見を優先し続ける中、糞便カルプロテクチン検査は、大腸がんの早期指標となり得る消化管内の炎症を特定するための不可欠なツールとして浮上しています。便検体中のカルプロテクチン濃度を測定するこの検査は、大腸内視鏡検査などのさらなる診断が必要かどうかを判断するための貴重な情報を医療専門家に記載しています。この非侵襲的なアプローチは、従来の診断法に比べて大きな利点があり、患者と医療提供者の双方にとって好ましい選択肢となっています。

糞便カルプロテクチン検査市場の成長に寄与するもう一つの重要な要因は、クローン病や潰瘍性大腸炎を含む炎症性腸疾患の有病率の増加です。消化管に炎症を引き起こすこれらの慢性疾患は、継続的なモニタリングと管理を必要とします。糞便カルプロテクチン検査は、IBD患者の疾患活動性を評価し、治療反応をモニタリングする上で重要な役割を果たしています。IBDの世界の罹患率の上昇に伴い、特に先進諸国では、糞便カルプロテクチン検査のような信頼性の高い非侵襲的診断ツールの需要が増加すると予想されます。侵襲的な処置を必要とせずに疾患の進行や再燃をモニターできることは、医療プロバイダーや患者の間でこの検査の採用を促進している重要な利点です。

予防医療の重要性に対する認識が高まっていることも、市場を牽引する重要な要因です。政府、医療団体、擁護団体は、大腸がんやその他の消化器疾患の早期発見にますます力を入れるようになっています。大腸がんの全国的なスクリーニング・プログラムが多くの国で実施されており、糞便カルプロテクチン検査はこれらのプログラムの一部としてしばしば含まれています。定期的なスクリーニングを受ける人が増えるにつれて、糞便カルプロテクチン検査の需要は増加すると予想されます。さらに、一般人口が大腸がんやIBDに関連するリスクをより認識するようになるにつれて、これらの疾患を早期に発見できる診断検査に対する需要が高まり、市場の成長をさらに後押ししています。

糞便カルプロテクチン検査の技術的進歩も市場拡大に寄与しています。より正確で、より迅速で、ユーザーフレンドリーな検査装置の開発により、糞便カルプロテクチン検査はより身近で効率的なものとなりました。自動分析装置や家庭用検査キットなどの技術革新により、医療プロバイダーも患者もこの診断ツールを使いやすくなりました。特に自動化システムは検査プロセスを合理化し、臨床検査室でのスループットを高め、検査効率を向上させました。一方、家庭用検査キットは、患者が自宅で快適に胃腸の健康状態をモニターできる便利な方法を記載しています。こうした進歩は、特に医療へのアクセスが限られている地域や、患者が独立して健康管理を行うことを好む地域において、糞便カルプロテクチン検査の普及を後押ししています。

市場の主要参入企業は、検査プロセスを合理化し、臨床現場での処理能力を向上させる使いやすい自動化システムの開発など、技術的進歩に注力しています。さらに、在宅検査ソリューションへの動向も高まっており、BIOHIT医療のような企業は、患者が遠隔で自分の状態をモニターできる自己検査キットを発表しています。また、各社が製品ポートフォリオを拡大し、市場での存在感を強めようとしているため、パートナーシップ、提携、買収も増加しています。競合戦略は、検査感度の向上、コスト削減、患者の利便性向上の必要性から大きな影響を受けており、各社はますます混雑する市場で自社製品を差別化するために継続的に取り組んでいます。

糞便カルプロテクチン検査市場レポートハイライト

• アッセイ別では、酵素結合免疫吸着アッセイが2024年に66.4%の最大売上シェアを占めました。その優位性の主要理由の1つは、炎症性腸疾患（IBD）や大腸がんなどの消化管疾患に関連する炎症を正確に検出できる高い感度と特異性です。
• 用途別では、炎症性腸疾患が市場を独占し、2024年には66.0%の最大シェアを占めました。これは、新興国だけでなく先進国でも有病率が増加していることに起因しています。
• 最終用途別では、病院・クリニックが2024年に54.7%の最大シェアを占めました。このセグメントの優位性は、病院で検査される患者数が多いことに起因しています。
• 北米が世界市場を独占したのは、多数の大手市場参入企業が存在するためです。北米はIBSやその他の胃疾患の有病率が高いです。さらに、医療インフラが発達していることも、この地域の市場開拓を後押ししています。
• アジア太平洋は、新興国市場全体で医療施設が開拓されていることから、2025～2030年までの予測期間においてCAGR 12.7%で最速の成長が見込まれています。さらに、予防的な定期検査への注目が高まっていることも、市場の成長を後押ししています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 糞便カルプロテクチン検査市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 糞便カルプロテクチン検査市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 糞便カルプロテクチン検査市場：アッセイ別、推定・動向分析

• アッセイ市場シェア、2024年と2030年
• セグメントダッシュボード
• アッセイによる世界の糞便カルプロテクチン検査市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 酵素免疫測定法
  • 酵素蛍光免疫測定法
  • 定量免疫クロマトグラフィー

第5章 糞便カルプロテクチン検査市場：用途別、推定・動向分析

• 用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 用途による世界の糞便カルプロテクチン検査市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 炎症性腸疾患
  • 大腸がん
  • その他

第6章 糞便カルプロテクチン検査市場：最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途による世界の糞便カルプロテクチン検査市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 病院とクリニック
  • 診断ラボ
  • 学術研究機関

第7章 糞便カルプロテクチン検査市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • Epitope Diagnostics Inc.
  • Hycult BIoTech
  • Actim
  • Eagle Biosciences, Inc.
  • OPERON
  • Svar Life Science
  • BUHLMANN
  • DRG International Inc.
  • ALPCO
  • Diazyme Laboratories

List of Tables

• Table. 1 List of Abbreviation
• Table. 2 North America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 3 North America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 4 North America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 5 North America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
• Table. 6 U.S. Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 7 U.S. Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 8 U.S. Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 9 Canada Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 10 Canada Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 11 Canada Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 12 Mexico Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 13 Mexico Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 14 Mexico Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 15 Europe Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 16 Europe Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 17 Europe Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 18 Europe Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
• Table. 19 Germany Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 20 Germany Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 21 Germany Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 22 UK Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 23 UK Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 24 UK Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 25 France Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 26 France Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 27 France Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 28 Italy Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 29 Italy Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 30 Italy Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 31 Spain Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 32 Spain Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 33 Spain Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 34 Sweden Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 35 Sweden Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 36 Sweden Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 37 Norway Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 38 Norway Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 39 Norway Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 40 Denmark Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 41 Denmark Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 42 Denmark Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 43 Asia Pacific Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 44 Asia Pacific Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 45 Asia Pacific Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 46 Asia Pacific Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
• Table. 47 China Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 48 China Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 49 China Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 50 Japan Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 51 Japan Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 52 Japan Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 53 India Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 54 India Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 55 India Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 56 Australia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 57 Australia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 58 Australia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 59 Thailand Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 60 Thailand Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 61 Thailand Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 62 South Korea Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 63 South Korea Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 64 South Korea Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 65 Latin America Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 66 Latin America Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 67 Latin America Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 68 Latin America Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
• Table. 69 Brazil Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 70 Brazil Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 71 Brazil Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 72 Argentina Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 73 Argentina Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 74 Argentina Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 75 Middle East and Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 76 Middle East and Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 77 Middle East and Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 78 Middle East and Africa Fecal Calprotectin Test market, by region, 2018 - 2030 (USD Million)
• Table. 79 South Africa Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 80 South Africa Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 81 South Africa Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 82 Saudi Arabia Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 83 Saudi Arabia Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 84 Saudi Arabia Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 85 UAE Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 86 UAE Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 87 UAE Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)
• Table. 88 Kuwait Fecal Calprotectin Test market, by assay, 2018 - 2030 (USD Million)
• Table. 89 Kuwait Fecal Calprotectin Test market, by application, 2018 - 2030 (USD Million)
• Table. 90 Kuwait Fecal Calprotectin Test market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Fecal Calprotectin Test: Market outlook
• Fig. 9 Fecal Calprotectin Test: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Fecal Calprotectin Test Market driver impact
• Fig. 15 Fecal Calprotectin Test Market restraint impact
• Fig. 16 Fecal Calprotectin Test Market strategic initiatives analysis
• Fig. 17 Fecal Calprotectin Test market: Assay movement analysis
• Fig. 18 Fecal Calprotectin Test market: Assay outlook and key takeaways
• Fig. 19 Enzyme-Linked Immunosorbent Assay market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Enzyme Fluroimmunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Quantitative Immunochromatography market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Fecal Calprotectin Test market: Application movement analysis
• Fig. 23 Fecal Calprotectin Test market: Application outlook and key takeaways
• Fig. 24 Inflammatory Bowel Disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Fecal Calprotectin Test market: End-Use movement analysis
• Fig. 28 Fecal Calprotectin Test market: End-Use outlook and key takeaways
• Fig. 29 Hospitals and Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
• Fig. 32 Global Fecal Calprotectin Test market: Regional movement analysis
• Fig. 33 Global Fecal Calprotectin Test market: Regional outlook and key takeaways
• Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 U.K. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Fecal Calprotectin Test Market Growth & Trends:

The global fecal calprotectin test market size is expected to reach USD 9.55 billion by 2030, registering a CAGR of 11.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of colorectal cancer, which has become one of the most common forms of cancer worldwide, is the major factor for the market growth. As healthcare systems continue to prioritize early detection to improve patient outcomes and reduce healthcare costs, fecal calprotectin testing has emerged as an essential tool for identifying inflammation in the gastrointestinal tract, which can be an early indicator of colorectal cancer. The test, which measures the concentration of calprotectin in stool samples, provides healthcare professionals with valuable information to determine whether further diagnostic procedures, such as colonoscopies, are necessary. This non-invasive approach offers a significant advantage over traditional diagnostic methods, making it a preferred option for both patients and healthcare providers.

Another significant factor contributing to the growth of the fecal calprotectin test market is the increasing prevalence of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. These chronic conditions, which cause inflammation in the digestive tract, require ongoing monitoring and management. Fecal calprotectin tests plays a crucial role in assessing disease activity and monitoring treatment response in patients with IBD. As the global incidence of IBD rises, particularly in developed countries, the demand for reliable, non-invasive diagnostic tools like fecal calprotectin tests is expected to increase. The ability to monitor disease progression and flare-ups without the need for invasive procedures is a key advantage that is driving the adoption of this test among healthcare providers and patients.

The growing awareness of the importance of preventive healthcare is also a significant factor driving the market. Governments, healthcare organizations, and advocacy groups are increasingly focusing on the early detection of colorectal cancer and other gastrointestinal disorders. National screening programs for colorectal cancer are being implemented in many countries, and fecal calprotectin tests are often included as part of these programs. As more individuals undergo routine screening, the demand for fecal calprotectin test is expected to rise. Additionally, as the general population becomes more aware of the risks associated with colorectal cancer and IBD, there is a growing demand for diagnostic tests that can detect these conditions early, further fueling market growth.

Technological advancements in fecal calprotectin test is also contributing to the market's expansion. The development of more accurate, faster, and user-friendly testing devices has made fecal calprotectin tests more accessible and efficient. Innovations such as automated analyzers and home testing kits have made it easier for both healthcare providers and patients to use this diagnostic tool. Automated systems, in particular, have streamlined the testing process, allowing for higher throughput in clinical laboratories and improving the efficiency of testing. Home test kits, on the other hand, provide patients with a convenient way to monitor their gastrointestinal health in the comfort of their own homes. These advancements are helping to drive the adoption of fecal calprotectin tests, particularly in regions where healthcare access may be limited or where patients prefer to manage their health independently.

Key players in the market are focusing on technological advancements, such as the development of user-friendly, automated systems that streamline the testing process and improve throughput in clinical settings. Additionally, there is a growing trend toward home-based testing solutions, with companies like BIOHIT Healthcare introducing self-test kits that allow patients to monitor their condition remotely. The market is also witnessing an increase in partnerships, collaborations, and acquisitions as companies seek to expand their product portfolios and strengthen their market presence. Competitive strategies are heavily influenced by the need to improve test sensitivity, reduce costs, and enhance patient convenience, with companies continuously working to differentiate their products in an increasingly crowded market.

Fecal Calprotectin Test Market Report Highlights:

• Based on assay, enzyme-linked immunosorbent assay accounted for the largest revenue share of 66.4% in 2024. One of the primary reasons for its dominance is its high sensitivity and specificity, which allows for accurate detection of inflammation associated with gastrointestinal disorders such as inflammatory bowel diseases (IBD) and colorectal cancer
• Based on application, inflammatory bowel disease dominated the market and accounted for the largest share of 66.0% in 2024.This can be attributed to the increasing prevalence of the disease in emerging as well as developed nations
• Based on end-use, the hospitals and clinics segment dominated the end use segments with the largest market share of 54.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals
• North America dominated the global market due to the presence of a large number of major market players. North America has a high prevalence of IBS and other gastric diseases. Furthermore, well-developed healthcare infrastructure fuels regional market growth
• Asia Pacific is expected to witness the fastest growth with a CAGR of 12.7% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Assay
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Assay outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Fecal Calprotectin Test Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Colorectal Cancer and IBD
    • 3.2.1.2. Growing Focus on Preventive Healthcare
    • 3.2.1.3. Growing demand for Non-invasive Testing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited Awareness in Some Regions
    • 3.2.2.2. High Cost of Testing in Certain Markets
• 3.3. Fecal Calprotectin Test Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Fecal Calprotectin Test Market: Assay Estimates & Trend Analysis

• 4.1. Assay Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Fecal Calprotectin Test Market by Assay Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Enzyme-Linked Immunosorbent Assay
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Enzyme Fluroimmunoassay
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Quantitative Immunochromatography
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Fecal Calprotectin Test Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Fecal Calprotectin Test Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Inflammatory Bowel Disease
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.4.2. Colorectal Cancer
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Others
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Fecal Calprotectin Test Market: End-Use Estimates & Trend Analysis

• 6.1. End-Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Fecal Calprotectin Test Market by End-Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals and Clinics
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Diagnostic Laboratories
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Academic and Research Institutes
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Fecal Calprotectin Test Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Target disease prevalence
    • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Target disease prevalence
    • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Target disease prevalence
    • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Target disease prevalence
    • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Target disease prevalence
    • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Target disease prevalence
    • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Target disease prevalence
    • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Target disease prevalence
    • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. Target disease prevalence
    • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Target disease prevalence
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Target disease prevalence
    • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Target disease prevalence
    • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Epitope Diagnostics Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Hycult Biotech
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Actim
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Eagle Biosciences, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. OPERON
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Svar Life Science
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. BUHLMANN
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. DRG International Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. ALPCO
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Diazyme Laboratories
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives